Evolv appears to have done early, sensible work on a new dietary ingredient, recognising hurdles like DPP-4 breakdown and oral absorption, engineering around them, and assembling safety data for New Dietary Ingredient Notification (NDIN) review
Why people use it: Most people interested in AOD-9604 are those whove previously tried semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) and want to transition to something else, often due to side effects
This tracker is appropriate for tirzepatide, compound GLP, and prescription drugs such as Monjaro, Ozempic, and Wegovy
Sales Analysis of GLP-1 Nutritional Support Market in the United Kingdom The CAGR in the United Kingdom climbed from about 7.6% during 2020 to 2024 to 10.9% in the 2025 to 2035 period, supported by the NHS's inclusion of GLP-1 supplementation for metabolic health
When combined with: Balanced nutrition Regular movement Adequate sleep Medical guidance GLP-1 therapy supports long-term metabolic health and sustainable weight management